| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 10.50 | 0.08 (+0.77%) | 9.16 - 14.99 | 85.3 thousand (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 10.50 |
|---|---|
| Previous Close | 10.42 |
| Day's Range | 10.45 - 10.55 |
| Market Cap | 154.0M |
| Avg Volume (10 Day) | 107.5K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.37 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
PR Newswire - Thursday 05/02/2013 4:00 PM ET
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
PR Newswire - Wednesday 05/01/2013 6:30 AM ET
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment
PR Newswire - Tuesday 04/30/2013 8:00 AM ET
OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013
PR Newswire - Thursday 04/25/2013 4:01 PM ET
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
PR Newswire - Tuesday 04/23/2013 4:01 PM ET
| OGXI | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 325.00% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.09 | |
| LT Debt/Equity | 0.07 | |
| Earnings Yield | -- | |
| Price/Sales | 6.46 |
| Company | Last | Change |
|---|---|---|
| 6.75 | -7.66% | |
| Aveo Pharmaceuticals Inc | 3.01 | +7.12% |
| Pacific Biosciences of California Inc | 2.42 | -2.02% |
| Geron Corp | 1.12 | -2.61% |
| Cempra Inc | 6.70 | -0.15% |
Data is delayed by at least 15 min.